Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Patients With Cancer: A Systematic Review and Trade-Off Analysis From 9 Randomized Controlled Trials.

Front Pharmacol · 2018 · PMC6005885 · PMID 29946255

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

In patients without cancer, as shown in Figures 3A,B , narrow NCB of NOACs was superior when compared with traditional anticoagulation (OR: 0.75, 95%CI: 0.54–0.96), and broad NCB showed a borderline significant result with NOACs vs. traditional anticoagulation (OR: 0.85, 95%CI: 0.67–1.04).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.